
4. Compounds of formula (I) according to claims 1 to 3, which are selected from the group consisting of:

- 1-(6-oxo-5,6-dihydro-4*H*-imidazo[4,5,1-ij]quinolin-2-yl)-4-pipéridinopiperidine
- 1-methyl-1-[1-(6-oxo-5,6-dihydro-4*H*-imidazo[4,5,1-*ij*]quinolin-2-yl)-4-piperidinyl]-piperidine
- 2-[4-(4-dimethylaminophenyl)piperazin-1-yl]4,5-dihydro-imidazo-[4,5,1-ij]quinolin-6-one
- 2-[4-(4-*tert*-butoxycarbonylaminophenyl)piperazin-1-yl]-4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-one
- 2-[4-(4-aminophenyl)piperazin-1-yl]4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-one
- 2-[4-(4-acetamidophenyl)pipérazin-1yl]4,5-dihydro-imidazo [4,5,1-ij]quinolin-6-onē
- 2-(4-n-propyl-piperazin-1-yl)-4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-one
- 2-(4-*tert*-butyloxycarbonyl-piperazin-1-yl)-4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-one
- 2-(piperazin-1-yl)-4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-one
- 2-(4-acetyl-piperazin-1-yl)-4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-one
- 2-[4-(4-pyridyl)-piperazin-1-yl)-4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-one
- 2-(4-benzyl-piperidin-1-yl)-4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-one
- 1-(6-oxo-5,6-dihydro-4*H*-imidazo[4,5,1-ij]quinolin-2-yl)-4-phenyl-4-piperidinecarboxamide
- 1-(6-oxo-5,6-dihydro-4*H*-imidazo[4,5,1-ij]quinolin-2-yl)-4-phenyl-4-aminopiperidine
- 2-[4-(4-hydroxyphenyl)-piperazin-1-yl]-4,5-dihydro-imidazo [4,5,1-ij]quinolin-6-one
- 2-[4-(4-fluorophenyl)-piperazin-1-yl]-4,5-dihydro-9-methyl-imidazo[4,5,1-ij]quinolin-6-one
- 1-[4-(4-fluorophenyl)-piperazin-1-yl]-3-methyl-8,9-dihydro-7*H*-2,9a-diazabenzo[cd]azulen-6-one
- 2-[4-(4-fluorophenyl)-piperazin-1-yl]-4,5-dihydro-7-methyl-imidazo[4,5,1-ij]quinolin-6-one
- 2-[4-(4-fluorophenyl)-piperazin-1-yl]-4,5-dihydro-8-methyl-imidazo[4,5,1-ij]quinolin-6-one
- 2-[4-(4-fluorophenyl)-piperazin-1-yl]-4,5-dihydro-7-methoxy-imidazo[4,5,1-ij]quinolin-6-one
- 2-[4-(4-methoxyphenyl)-piperazin-1-yl]-4,5-dihydro-imidazo [4,5,1-ij]quinolin-6-one
- 1-(6-oxo-5,6-dihydro-4*H*-imidazo[4,5,1-ij]quinolin-2-yl)-4*H*-4-dimethylaminopiperidine


in the form of enantiomers or diastereoisomers or mixtures of these various forms, including racemic mixtures, and also in the form of bases or addition salts with pharmaceutically acceptable acids.

~~4~~ 5. Process for preparing a compound of formula (I) according to any one of Claims 1 to ~~3~~ 4, characterized in that a derivative of formula (II):



(II)

in which R1, R2, R2' and n are as defined in Claim 1 and A represents a leaving group, is reacted in the presence of an amine of formula (III):



(III)

in which X, R3, R4 and m are as defined in Claim 1, in a solvent which may be an alcohol, an ether or a hydrocarbon, to give a compound of formula (I) according to Claim 1, the reaction being able to be carried out in the presence of a base, in the presence of alkali metal halides or in the presence of palladium-based or nickel-based catalysts.

~~5~~ 6. Compounds of formula (II) as defined in Claim ~~4~~ 5, which are useful as synthetic intermediates.

~~6~~ 7. Medicinal product, characterized in that it comprises a compound of formula (I) according to any one of Claims 1 to ~~3~~ 4.

~~7~~ 8. Pharmaceutical composition, characterized in that it comprises a compound of formula (I) according to any of claims 1 to ~~3~~ 4, and also one or more suitable pharmaceutical excipients.

~~8~~ 9. Use of a compound of formula (I) according to any one of Claims 1 to ~~3~~ 4, for the preparation of a medicinal product for preventing or treating disorders in which the enzyme poly (ADP-ribose) polymerase is involve.

~~9~~ 10. Use of a compound of formula (I) according to any one of Claims 1 to ~~3~~ 4, for the preparation of a medicinal product for preventing or treating myocardial infarction, cardiac ischemia, cardiac insufficiency, atherosclerosis, restenosis after PTCA or bypass, cerebral ischemia and cerebral infarction, caused by an ischemia, a trauma or a thromboembolic accident, neurodegenerative diseases such as Parkinson's diseases, Alzheimer's disease and Huntington's chorea, acute renal insuficiency, in particular that of ischemic origin or appearing after kidney transplant, heart transplant: treatment of grant rejection and accelerated atherosclerosis of grafts, inflammatory pathogies, immunological disorders, rheumatoid diseases, diabetes and pancreatitis, septic

shock, acute respiratory distress syndrome, tumours and metastases, autoimmune diseases, AIDS, hepatitis, psoriasis, vasculitis, ulcerative colitis, multiple sclerosis and myasthenia.


~~10~~ 11. Use of the compounds of formula (I) according to Claim 1, in which R1 = R2' = R3 = H, X = C, n = m = 1 and R4 represents either a 4-imidazolyl group or a 5-methyl-4-imidazolyl group, for the manufacture of a medicinal product for treating or preventing disorders in which the enzyme poly (ADP-ribose) polymerase is involved.

4. Compounds of formula (I) according to claims 1 to 3, which are selected from the group consisting of:

- 1-(6-oxo-5,6-dihydro-4*H*-imidazo[4,5,1-ij]quinolin-2-yl)-4-pipéridinopiperidine
- 1-methyl-1-[1-(6-oxo-5,6-dihydro-4*H*-imidazo[4,5,1-*ij*]quinolin-2-yl)-4-piperidinyl]-piperidine
- 2-[4-(4-dimethylaminophenyl)piperazin-1-yl]4,5-dihydro-imidazo-[4,5,1-ij]quinolin-6-one
- 2-[4-(4-*tert*-butoxycarbonylaminophenyl)piperazin-1-yl]-4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-one
- 2-[4-(4-aminophenyl)piperazin-1-yl]4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-one
- 2-[4-(4-acetamidophenyl)pipérazin-1yl]4,5-dihydro-imidazo [4,5,1-ij]quinolin-6-onē
- 2-(4-n-propyl-piperazin-1-yl)-4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-one
- 2-(4-*tert*-butyloxycarbonyl-piperazin-1-yl)-4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-one
- 2-(piperazin-1-yl)-4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-one
- 2-(4-acetyl-piperazin-1-yl)-4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-one
- 2-[4-(4-pyridyl)-piperazin-1-yl)-4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-one
- 2-(4-benzyl-piperidin-1-yl)-4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-one
- 1-(6-oxo-5,6-dihydro-4*H*-imidazo[4,5,1-ij]quinolin-2-yl)-4-phenyl-4-piperidinecarboxamide
- 1-(6-oxo-5,6-dihydro-4*H*-imidazo[4,5,1-ij]quinolin-2-yl)-4-phenyl-4-aminopiperidine
- 2-[4-(4-hydroxyphenyl)-piperazin-1-yl]-4,5-dihydro-imidazo [4,5,1-ij]quinolin-6-one
- 2-[4-(4-fluorophenyl)-piperazin-1-yl]-4,5-dihydro-9-methyl-imidazo[4,5,1-ij]quinolin-6-one
- 1-[4-(4-fluorophenyl)-piperazin-1-yl]-3-methyl-8,9-dihydro-7*H*-2,9a-diazabenzo[cd]azulen-6-one
- 2-[4-(4-fluorophenyl)-piperazin-1-yl]-4,5-dihydro-7-methyl-imidazo[4,5,1-ij]quinolin-6-one
- 2-[4-(4-fluorophenyl)-piperazin-1-yl]-4,5-dihydro-8-methyl-imidazo[4,5,1-ij]quinolin-6-one
- 2-[4-(4-fluorophenyl)-piperazin-1-yl]-4,5-dihydro-7-methoxy-imidazo[4,5,1-ij]quinolin-6-one
- 2-[4-(4-methoxyphenyl)-piperazin-1-yl]-4,5-dihydro-imidazo [4,5,1-ij]quinolin-6-one
- 1-(6-oxo-5,6-dihydro-4*H*-imidazo[4,5,1-ij]quinolin-2-yl)-4*H*-4-dimethylaminopiperidine


in the form of enantiomers or diastereoisomers or mixtures of these various forms, including racemic mixtures, and also in the form of bases or addition salts with pharmaceutically acceptable acids.

5. Process for preparing a compound of formula (I) according to any one of Claims 1 to 4, characterized in that a derivative of formula (II):



(II)

in which R1, R2, R2' and n are as defined in Claim 1 and A represents a leaving group, is reacted in the presence of an amine of formula (III):



(III)

in which X, R3, R4 and m are as defined in Claim 1, in a solvent which may be an alcohol, an ether or a hydrocarbon, to give a compound of formula (I) according to Claim 1, the reaction being able to be carried out in the presence of a base, in the presence of alkali metal halides or in the presence of palladium-based or nickel-based catalysts.

6. Compounds of formula (II) as defined in Claim 5, which are useful as synthetic intermediates.

7. Medicinal product, characterized in that it comprises a compound of formula (I) according to any one of Claims 1 to 4.

8. Pharmaceutical composition, characterized in that it comprises a compound of formula (I) according to any one of Claims 1 to 4, and also one or more suitable pharmaceutical excipients.

9. Use of a compound of formula (I) according to any one of Claims 1 to 4, for the preparation of a medicinal product for preventing or treating disorders in which the enzyme poly(ADP-ribose) polymerase is involved.

10. Use of a compound of formula (I) according to any one of Claims 1 to 4, for the preparation of a medicinal product for preventing or treating myocardial infarction, cardiac ischemia, cardiac insufficiency, atherosclerosis, restenosis after PTCA or bypass, cerebral ischemia and cerebral infarction, caused by an ischemia, a trauma or a thromboembolic accident, neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease and Huntington's chorea, acute renal insufficiency, in particular that of ischemic origin or appearing after kidney transplant, heart transplant: treatment of graft rejection and accelerated atherosclerosis of grafts, inflammatory pathologies, immunological disorders, rheumatoid diseases, diabetes and pancreatitis, septic

shock, acute respiratory distress syndrome, tumours and metastases, autoimmune diseases, AIDS, hepatitis, psoriasis, vasculitis, ulcerative colitis, multiple sclerosis and myasthenia.

11. Use of the compounds of formula (I) according to Claim 1, in which R1 = R2 = R2′ = R3 = H, X = C, n = m = 1 and R4 represents either a 4-imidazolyl group or a 5-methyl-4-imidazolyl group, for the manufacture of a medicinal product for treating or preventing disorders in which the enzyme poly(ADP-ribose) polymerase is involved.